Search
MSK researchers have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.
A Black community leader seeks prompt treatment for prostate cancer, avoiding the harsh toll the disease often takes on men like him.
New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists Andrea Cercek, MD, and Luis Diaz Jr., MD, demonstrates how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life.
Women want to understand and decrease their risk of breast cancer, and Nicole Saphier, MD, Director of Breast Imaging at MSK Monmouth, wants to ensure that women make the right decisions when it comes to their breast health this October, in honor of Breast Cancer Awareness Month, and every day.
Total neoadjuvant therapy is a viable treatment strategy for patients with locally advanced rectal cancer and is associated with the potential to sidestep surgical treatment.
Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases.
MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.